{"id":"W2890697824","doi":"10.1200/jco.2016.34.15_suppl.3564","title":"Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Internal medicine; Colorectal cancer; Gastroenterology; Adverse effect; Irinotecan; Cancer; Oncology; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001672128,0.0002794527,0.001495005,0.0002888478,0.00007215946,0.000007861043,0.000300681,0.0004285373,0.000186397],"category_scores_gemma":[0.0003468815,0.0001651911,0.0001308178,0.0003702593,0.0003966353,0.0003410986,0.00008272786,0.001023436,0.000002496655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004683368,"about_ca_system_score_gemma":0.001036222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008551061,"about_ca_topic_score_gemma":0.004020323,"domain_scores_codex":[0.9950501,0.001503391,0.00222906,0.0003997932,0.0004276971,0.0003900131],"domain_scores_gemma":[0.9946307,0.00147897,0.002571867,0.0001481766,0.0008956713,0.000274595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06885166,0.04835936,0.6780102,0.00002936298,0.0003051443,0.0003322829,0.000431687,0.0000550165,0.001925703,0.000009307051,0.0001611756,0.2015291],"study_design_scores_gemma":[0.1864443,0.07360409,0.7331513,0.0004147984,0.0002770894,0.00001810617,0.0004681802,0.00009156113,0.002492553,0.00002874188,0.002761025,0.0002483398],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956406,0.0002210492,0.00001864693,0.001062573,0.00202135,0.0008891489,0.00004236756,0.000007584301,0.00009669246],"genre_scores_gemma":[0.998714,0.0004644191,0.0001003711,0.000378315,0.0001984166,0.00006028095,0.000002915975,0.00002803712,0.00005323313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2012808,"threshold_uncertainty_score":0.6736298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.206843173479304,"score_gpt":0.5463825819132724,"score_spread":0.3395394084339684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}